B of A Securities Maintains Neutral on Moderna, Lowers Price Target to $110
Portfolio Pulse from Benzinga Newsdesk
B of A Securities has maintained a Neutral rating on Moderna (NASDAQ:MRNA) but has lowered its price target from $130 to $110.
September 13, 2024 | 4:20 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
B of A Securities has maintained a Neutral rating on Moderna but lowered the price target from $130 to $110, indicating a less optimistic outlook.
The lowering of the price target from $130 to $110 by B of A Securities suggests a less optimistic view on Moderna's stock performance. This could lead to a negative short-term impact on the stock price as investors may adjust their expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100